Resmed's shares fell by around 7% after the company forecast a softer than expected fiscal year 2027 (FY27) outlook due to suspended ventilator sales, ongoing macro uncertainty and inflation across electronic components and freight.
Releasing its FY26 and Q4 FY26 results concurrently, the California-based sleep apnoea specialist achieved revenues of around $5.65bn in FY26, denoting a year-over-year (YoY) uptick of 10%. Meanwhile, the company reported Q4 revenues of $1.46bn, indicative of a 9% uptick YoY.
Resmed's CEO, Mick Farrell, highlighted that Q4's "strong" results reflected "continued momentum" for its global business, sustained product demand and "disciplined" execution of its ongoing strategy.
The company's Q4, however, was marred by a correction and subsequent Class 1 recall from the US Food and Drug Administration (FDA) in July for certain of its Astral 100 and Astral 150 ventilators.
Citing other factors including fuel and freight costs, and ongoing macro uncertainty, Resmed now expects FY27 revenue to land in the $5.75bn to $5.85bn range, coming in below ******* ysts' expectations of $5.92bn, according to data compiled by the London Stock Exchange (LSEG) group and seen by Reuters.
#fy26 #ongoing
Releasing its FY26 and Q4 FY26 results concurrently, the California-based sleep apnoea specialist achieved revenues of around $5.65bn in FY26, denoting a year-over-year (YoY) uptick of 10%. Meanwhile, the company reported Q4 revenues of $1.46bn, indicative of a 9% uptick YoY.
Resmed's CEO, Mick Farrell, highlighted that Q4's "strong" results reflected "continued momentum" for its global business, sustained product demand and "disciplined" execution of its ongoing strategy.
The company's Q4, however, was marred by a correction and subsequent Class 1 recall from the US Food and Drug Administration (FDA) in July for certain of its Astral 100 and Astral 150 ventilators.
Citing other factors including fuel and freight costs, and ongoing macro uncertainty, Resmed now expects FY27 revenue to land in the $5.75bn to $5.85bn range, coming in below ******* ysts' expectations of $5.92bn, according to data compiled by the London Stock Exchange (LSEG) group and seen by Reuters.
#fy26 #ongoing
7 days ago
